S&N Class I recall
This article was originally published in The Gray Sheet
Executive Summary
FDA applies a Class I designation to Smith & Nephew's recall of 539 radiofrequency denervation probes on March 26. The firm began recalling the probes in January because they were mislabeled as sterile, which could lead to infections with associated risks of "organ failure and/or death," according to FDA. The probes are used with Smith & Nephew's Electrothermal 20S spine system in RF lesion procedures to relieve chronic pain. No injuries have been reported, according to the firm. Smith & Nephew is providing replacements to its 134 U.S. and international customers...
You may also be interested in...
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.
Human Cell-Secreted Proteins Offer A Wellspring Of Potential Therapeutics
CEO Hanadie Yousef leads Juvena Therapeutics in utilizing an AI-based platform that analyzes cell-secreted proteins to identify potential therapeutics. One of their first near-clinical assets could complement GLP-1s.